相关实验视频

Updated: Jul 24, 2025

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

预测HER2阳性乳腺癌患者晚期生存的生物学因素

Young-Joon Kang¹, Se Jeong Oh¹, Soo Youn Bae²

¹Department of Surgery, College of Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.

Scientific reports

|July 7, 2023

概括

对于HER2阳性乳腺癌患者来说,淋巴结状况是长期生存的关键预测因素,比瘤大小更重要. 患有晚期节点阳性疾病的患者需要延长临床观察和教育.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
病理学病理学病理学

背景情况:

HER2阳性乳腺癌与早期复发有关,但抗HER2疗法改善了长期结果.
识别晚期存活的因素对于管理HER2阳性乳腺癌至关重要.

研究的目的:

确定HER2阳性乳腺癌患者晚期生存的预测因素.
分析整体和乳腺癌特异性存活率 (BCSS) 超过5年的预后指标.

主要方法:

对20672名HER2-阳性乳腺癌I-III期患者的分析,分为≤60个月和>60个月的随访组.
多变量分析以确定与整体存活率和BCSS相关的因素.
对各种临床和病理因素计算的危险比率 (HRa).

主要成果:

在60个月内,导致整体存活率低下的因素包括年龄较大,晚期PT/PN阶段,高年级,入侵和HR阴性状态.
60个月以后,淋巴结阶段 (pN1-3) 和pT4是BCSS恶化的显著预测因素.
高龄和荷尔蒙受体阳性状态也与BCSS的恶化有关.

结论:

淋巴结状况是HER2阳性乳腺癌的长期预后的更重要的预测因素,而不是瘤 (T) 阶段.
患有HER2阳性乳腺癌的患者,特别是患有T4或结节阳性疾病的患者,需要延长临床观察和患者教育超过5年.

更多相关视频

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...